Insights into ASX Stocks
oOh!Media (ASX: OML): Takeover Clears ACCC Review, Further Approvals Pending
oOh!media’s (ASX: OML) A$1.70 takeover by I Squared has cleared the ACCC, with FIRB and NZ approvals pending. The stock sits near its 52-week high while investors await the scheme booklet and an early-November shareholder vote.
Silver Mines (ASX: SVL): Secures A$70M for BOWDENS: Capital Injection vs. Dilution Dynamics
Silver Mines (ASX: SVL) has secured a A$70 million placement at 14.5 cents to fund Bowdens approvals and royalty acquisitions, but the roughly 22% share issue and a 14.3% price drop put dilution in focus.
GR Engineering Services (ASX: GNG): Record Order Book Converts to Earnings, Valuation Now Close to Fair
GR Engineering’s record A$1.29 billion order book underpins FY27 revenue guidance of A$825–850 million, following record FY26 earnings. Strong project demand supports growth, but fixed-price execution risks, a stretched dividend payout and a demanding valuation warrant caution.
Aeris Resources (ASX: AIS): Strong Earnings Today, Longer-Term Value Beyond Cracow
Aeris delivered strong FY26 earnings and cash flow, underpinned by Tritton and Cracow, with no debt. Growth projects support longer-term value, but higher FY27 capital spending and Cracow’s limited reserves create execution risks.
OncoSil Medical (ASX: OSL): FDA Approval Lands and Commercial Execution Takes Centre Stage
OncoSil Medical is moving into commercial execution after US FDA approval, growing adoption in Spain, fresh institutional funding, and manufacturing progress, with investors watching reimbursement, hospital uptake, and demand.
.webp&w=828&q=75)
Telix Pharmaceuticals (ASX: TLX): $1.65B ITM Deal Expands Its Radiopharmaceutical Footprint
Telix Pharmaceuticals (ASX: TLX) has agreed to acquire ITM Isotope Technologies Munich for $1.65 billion, with up to $700 million in contingent consideration, expanding Telix’s isotope supply capabilities and radiopharmaceutical platform.